Cytori Therapeutics Inc. revealed that it has received approval from the Food and Drug Administration to sell its first device in the U. S. cleared for using a patient's own fat for cosmetic purposes, resulting in 19% increase in its shares.

Cytori's PureGraft system permits a patient's own fat tissue to be prepared in approximately 15 minutes for re-injection for so-called aesthetic contouring thereby resulting in high efficiencies in the operating room, decreasing surgery time and, enabling the processing of greater volumes, to include large defects.

The company claimed that the technology will be available in the first quarter of 2010. The company is also anticipating marketing approval for the product in Europe.

Adding to a great demand for cosmetic technology, Cytori said that more than 46,000 fat-grafting procedures were done in the U. S. last year.

The company is reportedly on cloud nine, as it continues to establish its strong hold in the market by developing latest products.